<DOC>
	<DOCNO>NCT00388206</DOCNO>
	<brief_summary>This observational study design follow patient metastatic locally advanced unresectable CRC locally advance metastatic NSCLC ( exclude predominant squamous histology ) receive Avastin combination first-line chemotherapy . Second-line metastatic CRC patient also eligible . Patients start Avastin contain therapy &lt; 4 month prior enrollment eligible .</brief_summary>
	<brief_title>A Study Avastin Combination With Chemotherapy Treatment Colorectal Cancer Non-Small Cell Lung Cancer ( ARIES )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed Informed Consent Form Metastatic locally advance unresectable CRC locally advance metastatic NSCLC ( exclude predominant squamous histology ) Eligible Avastin component intend therapy Firstline chemotherapy ( secondline chemotherapy CRC ) plus Avastin initiate â‰¤ 4 month prior study enrollment Any medical condition , include mental illness substance abuse , deem investigator likely interfere patient 's ability provide inform consent comply treatment followup , specify investigator Enrollment blind , placebocontrolled bevacizumab trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Avastin</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>lung cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>ARIES</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>